TxCell plans first-in-man trial of regulatory T cells

Having completed a Phase I/IIa study of Ovasave, a drug candidate from its first generation non-modified antigen-specific regulatory T cells (Tregs), TxCell expects to start a first-in-man study of a candidate from its next generation Treg platform in 2018. Mr. Stephane Boissel, TxCell’s CEO, explained to Scrip’s Mike Ward why the company accelerated its new platform and how it intends to focus on inflammatory and autoimmune diseases.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Stéphane Boissel – CEO, TxCell